AstraZeneca’s Imfinzi demonstrates significant survival benefits in Phase 3 ADRIATIC trial

Pallavi Madhiraju- April 7, 2024 0

In a significant advancement for cancer treatment, AstraZeneca's Imfinzi (durvalumab) has emerged as the first and only immunotherapy to show a survival benefit in a ... Read More

AstraZeneca’s PACIFIC-2 Phase 3 trial for Imfinzi in NSCLC falls short of primary endpoint

Pallavi Madhiraju- November 14, 2023 0

In the latest development in oncology research, AstraZeneca's PACIFIC-2 Phase III trial, involving Imfinzi (durvalumab) concurrently administered with platinum-based chemoradiotherapy (CRT), did not achieve statistical ... Read More

AstraZeneca’s IMFINZI/IMJUDO shows sustained OS in Phase 3 liver cancer study

Pallavi Madhiraju- June 29, 2023 0

AstraZeneca's IMFINZI (durvalumab) combined with IMJUDO (tremelimumab-actl) has demonstrated an enduring overall survival (OS) benefit in patients with advanced hepatocellular carcinoma (HCC), according to the ... Read More

AstraZeneca reports positive results for phase 2 COAST trial of oleclumab and monalizumab

pallavi123- September 18, 2021 0

AstraZeneca has reported positive results from the COAST phase 2 trial of its oleclumab or monalizumab in combination with Imfinzi (durvalumab) in patients with non-small ... Read More

AstraZeneca’s Imfinzi garners positive opinion from CHMP for NSCLC treatment

pharmanewsdaily- July 29, 2018 0

AstraZeneca has reached a crucial milestone as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a ... Read More